• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    10 Health Care Stocks Whale Activity In Today's Session

    6/25/24 1:35:24 PM ET
    $ABBV
    $GEHC
    $GILD
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Electronics
    Health Care
    Get the next $ABBV alert in real time by email

    This whale alert can help traders discover the next big trading opportunities.

    Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

    Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels.

    Here's the list of options activity happening in today's session:

    Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume
    PFE CALL SWEEP BEARISH 07/19/24 $28.00 $72.8K 28.1K 2.7K
    MRK CALL SWEEP BEARISH 07/19/24 $140.00 $78.8K 3.1K 1.1K
    VRNA PUT SWEEP BULLISH 07/19/24 $15.00 $75.0K 3.5K 375
    GILD CALL SWEEP BEARISH 06/20/25 $75.00 $37.2K 663 133
    VKTX PUT TRADE NEUTRAL 01/17/25 $37.00 $226.0K 53 106
    ABBV CALL TRADE BEARISH 06/28/24 $170.00 $51.0K 580 48
    RXRX CALL SWEEP BULLISH 12/20/24 $7.00 $25.9K 371 40
    GEHC CALL SWEEP NEUTRAL 08/16/24 $80.00 $31.9K 10 13
    LLY CALL TRADE BULLISH 12/18/26 $760.00 $28.4K 17 11
    MRNA CALL TRADE BULLISH 10/18/24 $115.00 $39.8K 163 7

    Explanation

    These itemized elaborations have been created using the accompanying table.

    • Regarding PFE (NYSE:PFE), we observe a call option sweep with bearish sentiment. It expires in 24 day(s) on July 19, 2024. Parties traded 998 contract(s) at a $28.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $72.8K, with a price of $73.0 per contract. There were 28115 open contracts at this strike prior to today, and today 2711 contract(s) were bought and sold.

    • For MRK (NYSE:MRK), we notice a call option sweep that happens to be bearish, expiring in 24 day(s) on July 19, 2024. This event was a transfer of 2000 contract(s) at a $140.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $78.8K, with a price of $39.0 per contract. There were 3133 open contracts at this strike prior to today, and today 1148 contract(s) were bought and sold.

    • Regarding VRNA (NASDAQ:VRNA), we observe a put option sweep with bullish sentiment. It expires in 24 day(s) on July 19, 2024. Parties traded 250 contract(s) at a $15.00 strike. This particular put needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $75.0K, with a price of $300.0 per contract. There were 3515 open contracts at this strike prior to today, and today 375 contract(s) were bought and sold.

    • For GILD (NASDAQ:GILD), we notice a call option sweep that happens to be bearish, expiring in 360 day(s) on June 20, 2025. This event was a transfer of 71 contract(s) at a $75.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $37.2K, with a price of $525.0 per contract. There were 663 open contracts at this strike prior to today, and today 133 contract(s) were bought and sold.

    • Regarding VKTX (NASDAQ:VKTX), we observe a put option trade with neutral sentiment. It expires in 206 day(s) on January 17, 2025. Parties traded 400 contract(s) at a $37.00 strike. The total cost received by the writing party (or parties) was $226.0K, with a price of $565.0 per contract. There were 53 open contracts at this strike prior to today, and today 106 contract(s) were bought and sold.

    • For ABBV (NYSE:ABBV), we notice a call option trade that happens to be bearish, expiring in 3 day(s) on June 28, 2024. This event was a transfer of 230 contract(s) at a $170.00 strike. The total cost received by the writing party (or parties) was $51.0K, with a price of $222.0 per contract. There were 580 open contracts at this strike prior to today, and today 48 contract(s) were bought and sold.

    • For RXRX (NASDAQ:RXRX), we notice a call option sweep that happens to be bullish, expiring in 178 day(s) on December 20, 2024. This event was a transfer of 70 contract(s) at a $7.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $25.9K, with a price of $370.0 per contract. There were 371 open contracts at this strike prior to today, and today 40 contract(s) were bought and sold.

    • Regarding GEHC (NASDAQ:GEHC), we observe a call option sweep with neutral sentiment. It expires in 52 day(s) on August 16, 2024. Parties traded 106 contract(s) at a $80.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $31.9K, with a price of $300.0 per contract. There were 10 open contracts at this strike prior to today, and today 13 contract(s) were bought and sold.

    • Regarding LLY (NYSE:LLY), we observe a call option trade with bullish sentiment. It expires in 906 day(s) on December 18, 2026. Parties traded 1 contract(s) at a $760.00 strike. The total cost received by the writing party (or parties) was $28.4K, with a price of $28495.0 per contract. There were 17 open contracts at this strike prior to today, and today 11 contract(s) were bought and sold.

    • Regarding MRNA (NASDAQ:MRNA), we observe a call option trade with bullish sentiment. It expires in 115 day(s) on October 18, 2024. Parties traded 14 contract(s) at a $115.00 strike. The total cost received by the writing party (or parties) was $39.8K, with a price of $2845.0 per contract. There were 163 open contracts at this strike prior to today, and today 7 contract(s) were bought and sold.

    Options Alert Terminology
    - Call Contracts: The right to buy shares as indicated in the contract.
    - Put Contracts: The right to sell shares as indicated in the contract.
    - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it.
    - Premium/Option Price: The price of the contract.

    For more information, visit our Guide to Understanding Options Alerts or read more about unusual options activity.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABBV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABBV
    $GEHC
    $GILD
    $LLY

    CompanyDatePrice TargetRatingAnalyst
    Pfizer Inc.
    $PFE
    2/20/2026$25.00Underweight
    Barclays
    Merck & Company Inc.
    $MRK
    2/20/2026$140.00Overweight
    Barclays
    Gilead Sciences Inc.
    $GILD
    2/20/2026$155.00Equal Weight
    Barclays
    Eli Lilly and Company
    $LLY
    2/20/2026$1350.00Overweight
    Barclays
    AbbVie Inc.
    $ABBV
    2/20/2026$275.00Overweight
    Barclays
    Merck & Company Inc.
    $MRK
    2/13/2026$150.00Hold → Buy
    Deutsche Bank
    Pfizer Inc.
    $PFE
    2/12/2026$27.00Outperform → Neutral
    Daiwa Securities
    Gilead Sciences Inc.
    $GILD
    2/11/2026$140.00 → $170.00Buy
    Needham
    More analyst ratings

    $ABBV
    $GEHC
    $GILD
    $LLY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & CFO Montarce Lucas bought $494,627 worth of shares (715 units at $691.79), increasing direct ownership by 5% to 14,685 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/15/25 4:13:02 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Alvarez Ralph bought $500,473 worth of shares (758 units at $660.25) (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/14/25 4:12:51 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & Pres., Lilly Oncology Van Naarden Jacob bought $647,360 worth of shares (1,000 units at $647.36), increasing direct ownership by 5% to 20,562 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/13/25 4:15:45 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $GEHC
    $GILD
    $LLY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States

    Investment marks continued progress against AbbVie's $100 billion commitment to U.S. research and development (R&D) and capital investments, including manufacturing, over the next decadeTwo new facilities will be built to add advanced manufacturing capabilities to support the production of next-generation neuroscience and obesity medicinesConstruction will begin in spring 2026, with the site fully operational in 2029NORTH CHICAGO, Ill., Feb. 23, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced a new $380 million investment to build two new active pharmaceutical ingredient (API) manufacturing facilities at its current North Chicago, Illinois, campus. These new state-of-the-art faciliti

    2/23/26 11:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

    Pfizer Inc. (NYSE:PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 10:30 a.m. EST. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. The transcript and webcast replay of the discussion will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live discussion and will be accessible for at least 90 days. About Pfizer: Breakthrough

    2/23/26 10:00:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen

    Used by millions of patients worldwide, the KwikPen® for single-patient use provides patients with a new option to receive Zepbound®Zepbound patients can access all doses in either multi-dose KwikPen or single-dose vial at the same self-pay price, starting at $299, available by prescription now through LillyDirect*INDIANAPOLIS, Feb. 23, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound® (tirzepatide) to include the four-dose single-patient use KwikPen® that delivers a full month of treatment in one device. With the Zepbound KwikPen, Lilly is expanding choice and helping ensure patients and

    2/23/26 9:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $GEHC
    $GILD
    $LLY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-6) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215973, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-8) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215974, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-9) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/13/2024. Application Category: NDA, Application Number: 215973, Application Classification: Manufacturing (CMC)

    11/15/24 4:36:27 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABBV
    $GEHC
    $GILD
    $LLY
    SEC Filings

    View All

    Gilead Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - GILEAD SCIENCES, INC. (0000882095) (Filer)

    2/23/26 6:46:27 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 filed by Moderna Inc.

    S-8 - Moderna, Inc. (0001682852) (Filer)

    2/20/26 4:03:07 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Moderna Inc.

    10-K - Moderna, Inc. (0001682852) (Filer)

    2/20/26 4:02:04 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABBV
    $GEHC
    $GILD
    $LLY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Pfizer with a new price target

    Barclays initiated coverage of Pfizer with a rating of Underweight and set a new price target of $25.00

    2/20/26 8:25:15 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Merck with a new price target

    Barclays initiated coverage of Merck with a rating of Overweight and set a new price target of $140.00

    2/20/26 8:25:04 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Gilead Sciences with a new price target

    Barclays initiated coverage of Gilead Sciences with a rating of Equal Weight and set a new price target of $155.00

    2/20/26 8:24:53 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABBV
    $GEHC
    $GILD
    $LLY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, R&D and CSO Thakkar Roopal was granted 18,137 shares, increasing direct ownership by 43% to 60,413 units (SEC Form 4)

    4 - AbbVie Inc. (0001551152) (Issuer)

    2/20/26 6:36:48 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, CHIEF COMMERCIAL OFFICER Stewart Jeffrey Ryan was granted 53,749 shares, increasing direct ownership by 101% to 106,983 units (SEC Form 4)

    4 - AbbVie Inc. (0001551152) (Issuer)

    2/20/26 6:35:24 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, GC AND SECRETARY Siatis Perry C was granted 33,518 shares, increasing direct ownership by 726% to 38,137 units (SEC Form 4)

    4 - AbbVie Inc. (0001551152) (Issuer)

    2/20/26 6:35:21 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $GEHC
    $GILD
    $LLY
    Leadership Updates

    Live Leadership Updates

    View All

    Merck Evolves Human Health Operating Structure to Support Portfolio Execution

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today highlighted steps to evolve the structure of its Human Health organization to ensure strong commercial execution of launches across diverse therapeutic areas, positioning the company for continued commercial success. As part of this evolution, Merck is organizing its Human Health business into an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit. This structure will enable Merck to sustain long-term leadership in oncology, while maintaining a sharp focus in support of a growing number of launches across an increasingly broad and diverse portfolio. In support of the new Human He

    2/23/26 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    $ABBV
    $GEHC
    $GILD
    $LLY
    Financials

    Live finance-specific insights

    View All

    Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

    Pfizer Inc. (NYSE:PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 10:30 a.m. EST. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. The transcript and webcast replay of the discussion will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live discussion and will be accessible for at least 90 days. About Pfizer: Breakthrough

    2/23/26 10:00:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Declares Quarterly Dividend

    NORTH CHICAGO, Ill., Feb. 19, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE:ABBV) today declared a quarterly cash dividend of $1.73 per share.  The cash dividend is payable May 15, 2026, to stockholders of record at the close of business on April 15, 2026.Since the company's inception in 2013, AbbVie has increased its dividend by more than 330 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of

    2/19/26 9:37:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25

    Salt Lake City, UT, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026, before the open of the financial markets. Recursion will host a (L)earnings Call on February 25, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT. The company will broadcast the live stream from Recursion's X, LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://forms.gle/TQ4vgUTLKsFm

    2/18/26 8:30:00 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABBV
    $GEHC
    $GILD
    $LLY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Verona Pharma plc

    SC 13G/A - Verona Pharma plc (0001657312) (Subject)

    11/14/24 5:46:11 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Verona Pharma plc

    SC 13G/A - Verona Pharma plc (0001657312) (Subject)

    11/14/24 4:50:28 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Verona Pharma plc

    SC 13G - Verona Pharma plc (0001657312) (Subject)

    11/14/24 4:31:56 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care